At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms. We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide. To learn more about us, visit https://biontech.de/ Our privacy statement can be found here: https://www.biontech.com/int/en/home/data-privacy-statement.html
View Top Employees from BioNTech SEWebsite | https://biontech.de/ |
Ticker | BNTX |
Revenue | $24.6 billion |
Funding | $1.3 billion |
Employees | 4,389 (2,978 on RocketReach) |
Founded | 2008 |
Address | An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE |
Phone | +49 4961 319084 |
Fax | +49 6131 9084390 |
Technologies |
JavaScript,
HTML,
Twitter
+82 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Biopharma, Personalized Oncology Therapy, Healthcare, Drug Discovery, Health Care, Science and Engineering, Pharmaceutical |
Web Rank | 671478 |
Keywords | Cancer Treatment, Biotechnology, Cancer Research, Drug Development And Manufacturing, Clinical Trials |
Competitors | Dendreon, Juno Therapeutics, Inc., Kite Pharma, Nektar Therapeutics, Seagen |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular BioNTech SE employee's phone or email?
The BioNTech SE annual revenue was $24.6 billion in 2024.
Andreas Kuhn is the Senior Vice President RNA Biochemistry and Manufacturing of BioNTech SE.
2,978 people are employed at BioNTech SE.
BioNTech SE is based in Mainz, Rhineland-Palatinate.
The NAICS codes for BioNTech SE are [32541, 3254, 325, 32, 54, 541].
The SIC codes for BioNTech SE are [873, 87].